About Amryt Pharma PLC (LON:FAST)
Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company's lead products include AP 101 and AP102. AP101 (Episalvan) is a potential treatment for Epidermolysis Bullosa (EB), and it is in Phase III clinical trials. AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases. The Company holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union (EU) and other territories, including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol (bad cholesterol) from the blood.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: LON:FAST
- CUSIP: N/A
- Web: www.amrytpharma.com/
- 52 Week Range: GBX 1.85 - GBX 3.90
- Trailing P/E Ratio: N/A
- P/E Growth: 0
- Net Margins: -223.72%
- Return on Equity: -104.94%
- Return on Assets: -40.64%
- Average Volume: 939,809 shs.
Frequently Asked Questions for Amryt Pharma PLC (LON:FAST)
What is Amryt Pharma PLC's stock symbol?
Amryt Pharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "FAST."
Where is Amryt Pharma PLC's stock going? Where will Amryt Pharma PLC's stock price be in 2017?
2 brokerages have issued 12 month target prices for Amryt Pharma PLC's stock. Their forecasts range from GBX 60 to GBX 65. On average, they expect Amryt Pharma PLC's stock price to reach GBX 62.50 in the next year. View Analyst Ratings for Amryt Pharma PLC.
Who are some of Amryt Pharma PLC's key competitors?
Some companies that are related to Amryt Pharma PLC include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Celgene Corporation (CELG), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP) and Teva Pharmaceutical Industries Limited (TEVA).
Who are Amryt Pharma PLC's key executives?
Amryt Pharma PLC's management team includes the folowing people:
- Joe Wiley, Chief Executive Officer, Executive Director
- Rory Nealon, Chief Financial Officer, Chief Operating Officer, Executive Director, Company Secretary
- Harry Thomas Stratford, Independent Non-Executive Chairman of the Board
- James Culverwell, Senior Non-Executive Independent Director
- Ray Stafford, Non-Executive Independent Director
- Markus Ziener, Non-Executive Independent Director
How do I buy Amryt Pharma PLC stock?
Shares of Amryt Pharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Amryt Pharma PLC's stock price today?
MarketBeat Community Rating for Amryt Pharma PLC (LON FAST)MarketBeat's community ratings are surveys of what our community members think about Amryt Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Amryt Pharma PLC stock can currently be purchased for approximately GBX 2.97.
Consensus Ratings for Amryt Pharma PLC (LON:FAST) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||GBX 62.50|Consensus Price Target History for Amryt Pharma PLC (LON:FAST)
Analysts' Ratings History for Amryt Pharma PLC (LON:FAST)
(Data available from 10/23/2015 forward)
|9/24/2017||Beaufort Securities||Reiterated Rating||Speculative Buy||GBX 65|
|4/24/2017||Stifel Nicolaus||Reiterated Rating||Buy||GBX 60|
Earnings History for Amryt Pharma PLC (LON:FAST)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Amryt Pharma PLC (LON:FAST)
Current Year EPS Consensus Estimate: $-0.33 EPS
Dividend History for Amryt Pharma PLC (LON:FAST)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Amryt Pharma PLC (LON:FAST)Insider Trades by Quarter for Amryt Pharma PLC (LON:FAST)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
Headline Trends for Amryt Pharma PLC (LON:FAST)
Latest Headlines for Amryt Pharma PLC (LON:FAST)
Loading headlines, please wait.
Amryt Pharma PLC (FAST) Chart for Monday, October, 23, 2017